학술논문
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial
Document Type
Article
Author
Knight, E.M.P.; Amin, S.; Bahi-Buisson, N.; Benke, T.A.; Demarest, S.T.; Cross, J.H.; Olson, H.E.; Specchio, N.; Fleming, T.R.; Aimetti, A.A.; Gasior, M.; Devinsky, O.; Belousova, E.; Belyaev, O.; Ben-Zeev, B.; Brunklaus, A.; Ciliberto, M.A.; Darra, F.; Davis, R.; De Giorgis, V.; Doronina, O.; Fahey, M.; Guerrini, R.; Heydemann, P.; Khaletskaya, O.; Lisewski, P.; Marsh, E.D.; Moosa, A.N.; Perry, S.; Philip, S.; Rajaraman, R.R.; Renfroe, B.; Saneto, R.P.; Scheffer, I.E.; Sogawa, Y.; Suter, B.; Sweney, M.T.; Tarquinio, D.; Veggiotti, P.; Wallace, G.; Weisenberg, J.; Wilfong, A.; Wirrell, E.C.; Zafar, M.; Zolnowska, M.
Source
In: The Lancet Neurology . (The Lancet Neurology, May 2022, 21(5):417-427)
Subject
Language
English
ISSN
14744465
14744422
14744422